Search results for "Rape"

showing 10 items of 2178 documents

Considerations for an in vitro, cell-based testing platform for detection of adverse drug-induced inotropic effects in early drug development. Part 1…

2019

Drug-induced effects on cardiac contractility can be assessed through the measurement of the maximal rate of pressure increase in the left ventricle (LVdP/dtmax) in conscious animals, and such studies are often conducted at the late stage of preclinical drug development. Detection of such effects earlier in drug research using simpler, in vitro test systems would be a valuable addition to our strategies for identifying the best possible drug development candidates. Thus, testing platforms with reasonably high throughput, and affordable costs would be helpful for early screening purposes. There may also be utility for testing platforms that provide mechanistic information about how a given d…

0301 basic medicineInotropeDrugIn vitro testComputer sciencemedia_common.quotation_subjectcardiomyocyteReviewCardiomyocyteStem cellsContractilityInotropic statecontractilityContractility03 medical and health sciences0302 clinical medicinestem cellsmyocardiumPharmacology (medical)media_commoninotropic statePharmacologyMyocardiumlcsh:RM1-950Pre-clinical development030104 developmental biologylcsh:Therapeutics. PharmacologyDrug developmentRisk analysis (engineering)030220 oncology & carcinogenesisPressure increaseCell based
researchProduct

Berberine Mediated Positive Inotropic Effects on Rat Hearts via a Ca2+-Dependent Mechanism

2020

Previous studies showed that berberine, an alkaloid from Coptis Chinensis Franch, might exert a positive inotropic effect on the heart. However, the underlying mechanisms were unclear. Here, we reported that berberine at 10-20 µM increased the left ventricular (LV) developed pressure and the maximal rate of the pressure rising, and it increased the maximal rate of the pressure descending at 20 µM in Langendorff-perfused isolated rat hearts. These effects diminished with the concentration of berberine increasing to 50 µM. In the concentration range of 50-300 µM, berberine increased the isometric tension of isolated left ventricular muscle (LVM) strips with or without electrical stimulations,…

0301 basic medicineInotropeheartPharmacology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBerberineNifedipineberberineExtracellularmedicineMyocytePharmacology (medical)positive inotropic effectPharmacologybiologyAlkaloidlcsh:RM1-950Coptis chinensisNa+biology.organism_classificationCa2+030104 developmental biologylcsh:Therapeutics. Pharmacologychemistry030220 oncology & carcinogenesisIntracellularmedicine.drugFrontiers in Pharmacology
researchProduct

Redox Status, Dose and Antioxidant Intake in Healthcare Workers Occupationally Exposed to Ionizing Radiation

2020

The purpose of this study was to evaluate the relationship between blood redox status, dose and antioxidant dietary intake of different hospital staff groups exposed to low doses of ionizing radiation (LDIR) (Interventional Radiology and Cardiology, Radiation Oncology, and Nuclear Medicine) and non-exposed. Personal dose equivalent (from last year and cumulative), plasma antioxidant markers (total antioxidant capacity, extracellular superoxide dismutase activity, and glutathione/oxidized glutathione ratio), oxidative stress markers (nitrites and nitrates, and lipid peroxidation) and dietary intake (antioxidant capacity using ORAC values) were collected and analyzed from 28 non-exposed healt…

0301 basic medicineIonizing radiationAntioxidantPhysiologyThiobarbituric acidmedicine.medical_treatmentClinical BiochemistryPhysiologymedicine.disease_causeBiochemistryArticleIonizing radiationLipid peroxidation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOxygen radical absorbance capacity (ORAC)TBARSMedicineMolecular Biologypersonal dose equivalentPersonal dose equivalentbusiness.industryEquivalent doselcsh:RM1-950Antioxidant-oxidant statusCell BiologyGlutathioneoccupational exposureOccupational exposure030104 developmental biologyantioxidant-oxidant statuslcsh:Therapeutics. Pharmacologychemistryoxygen radical absorbance capacity (ORAC)030220 oncology & carcinogenesisbusinessionizing radiationOxidative stressAntioxidants
researchProduct

Comparison of time and dose dependent gene expression and affected pathways in primary human fibroblasts after exposure to ionizing radiation

2020

Abstract Background Exposure to ionizing radiation induces complex stress responses in cells, which can lead to adverse health effects such as cancer. Although a variety of studies investigated gene expression and affected pathways in human fibroblasts after exposure to ionizing radiation, the understanding of underlying mechanisms and biological effects is still incomplete due to different experimental settings and small sample sizes. Therefore, this study aims to identify the time point with the highest number of differentially expressed genes and corresponding pathways in primary human fibroblasts after irradiation at two preselected time points. Methods Fibroblasts from skin biopsies of…

0301 basic medicineIonizing radiationTime FactorsDNA damageCellHigh doseIonizing radiationlcsh:BiochemistryGene-radiation interaction03 medical and health sciences0302 clinical medicineRadiation IonizingGene expressionGeneticsmedicineHumanslcsh:QD415-436IrradiationMolecular BiologyGeneGenetics (clinical)Gene-radiation interaction ; RNA sequencing ; Childhood cancer ; High dose ; Fibroblasts ; Low dose ; Second primary neoplasm ; IPA ; Ionizing radiationCells CulturedChemistryGene Expression Profilinglcsh:RM1-950Second primary neoplasmCancerComputational BiologyRNA sequencingDose-Response Relationship RadiationFibroblastsmedicine.diseaseCell biology030104 developmental biologymedicine.anatomical_structurelcsh:Therapeutics. PharmacologyLow doseGene Expression Regulation030220 oncology & carcinogenesisIPACase-Control StudiesMolecular MedicineSignal transductionChildhood cancerResearch ArticleSignal TransductionMolecular Medicine
researchProduct

Opportunities and challenges for drug development: public-private partnerships, adaptive designs and big data

2016

Drug development faces the double challenge of increasing costs and increasing pressure on pricing. To avoid that lack of perceived commercial perspective will leave existing medical needs unmet, pharmaceutical companies and many other stakeholders are discussing ways to improve the efficiency of drug Research and Development. Based on an international symposium organized by the Medical School of the University of Duisburg-Essen (Germany) and held in January 2016, we discuss the opportunities and challenges of three specific areas, i.e., public-private partnerships, adaptive designs and big data. Public-private partnerships come in many different forms with regard to scope, duration and typ…

0301 basic medicineLeverage (finance)Big dataMedizinReviewAppropriate useadaptive trial design03 medical and health sciencesDrug DevelopmentInformed consentinvestigator-initiated studiesbig dataPharmacology (medical)RepurposingPharmacologyInformed Consentbusiness.industryManagement sciencelcsh:RM1-950Public relationsEuphemismpublic-private partnershipPublic–private partnership030104 developmental biologylcsh:Therapeutics. PharmacologyDrug developmentPrivacyBusinesspublic–private partnershipFrontiers in Pharmacology
researchProduct

Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease.

2018

L-DOPA is still the most effective pharmacological therapy for the treatment of motor symptoms in Parkinson's disease (PD) almost four decades after it was first used. Deep brain stimulation (DBS) is a safe and highly effective treatment option in patients with PD. Even though a clear understanding of the mechanisms of both treatment methods is yet to be obtained, the combination of both treatments is the most effective standard evidenced-based therapy to date. Recent studies have demonstrated that DBS is a therapy option even in the early course of the disease, when first complications arise despite a rigorous adjustment of the pharmacological treatment. The unique feature of this therapeu…

0301 basic medicineLevodopaParkinson's diseaseDeep brain stimulationglobus pallidus internus (GPi)medicine.medical_treatmentParkinson's diseaseCentral nervous systemStimulationDiseaseReviewlcsh:RC346-42903 medical and health sciencesTherapeutic approach0302 clinical medicinemedicinelevodopadeep brain stimulation (DBS)lcsh:Neurology. Diseases of the nervous systembusiness.industryDopaminergicmedicine.diseasenervous system diseases030104 developmental biologymedicine.anatomical_structureNeurologyNeurology (clinical)businessNeurosciencesubthalamic nucleus (STN)030217 neurology & neurosurgerymedicine.drugFrontiers in neurology
researchProduct

Pre-dopa Deep Brain Stimulation: Is Early Deep Brain Stimulation Able to Modify the Natural Course of Parkinson’s Disease?

2020

Deep brain stimulation (DBS) is an established therapy for the management of Parkinson's disease (PD). However, DBS is indicated as the disease progresses and motor complications derived from pharmacological therapy arise. Here, we evaluate the potential of DBS prior to levodopa (L-Dopa) in improving quality of life (QoL), challenging the state of the art for DBS therapy. We present data on clinical manifestation, decision finding during early indication to DBS, and trajectories after DBS. We further discuss current paradigms for DBS and hypothesize on possible mechanisms. Six patients, between 50 and 67 years old, presenting at least 5 years of PD symptoms, and without L-Dopa therapy initi…

0301 basic medicineLevodopamedicine.medical_specialtyDeep brain stimulationParkinson's diseasemedicine.medical_treatmentDiseaselcsh:RC321-57103 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationQuality of lifemedicineAdverse effectlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal Researchsubthalamic nucleusbusiness.industryGeneral Neuroscienceearly deep brain stimulationmedicine.diseasenervous system diseasesdeep brain stimulationClinical trialSubthalamic nucleusearly intervention030104 developmental biologysurgical procedures operativenervous systemParkinson’s diseasebusinesstherapeutics030217 neurology & neurosurgerymedicine.drugNeuroscienceFrontiers in Neuroscience
researchProduct

From waste to health: sustainable exploitation of grape pomace seed extract to manufacture antioxidant, regenerative and prebiotic nanovesicles withi…

2020

AbstractPomace seed extract loaded vesicles were prepared as promising technological and green solution to exploit agri-food wastes and by-products, and develop high value-added products for human health. An antioxidant extract rich in bioactive compounds (epicatechins, catechin, gallic acid, quercetin and procynidins) was obtained from the seeds isolated from the pomace of Cannonau red grape cultivar. The extract was incorporated into phospholipid vesicles ad hoc formulated for intestinal delivery, by combining them, for the first time, whit a maltodextrin (Glucidex). Glucidex-transfersomes, glucidex-hyalurosomes and glucidex-hyalutransferomes were prepared, characterized and tested. Gluci…

0301 basic medicineLimosilactobacillus reuteriAntioxidantmedicine.medical_treatmentlcsh:MedicinePolysorbatesAntioxidantschemistry.chemical_compound0302 clinical medicineRecyclingVitisGallic acidFood scienceHyaluronic AcidHydrogen peroxidelcsh:SciencePhospholipidsDrug CarriersMultidisciplinaryfood and beveragesCatechinMaltodextrinIntestinesPolifenolsColonic NeoplasmsSeedsQuercetinPrebiòticsGrapesArticle03 medical and health sciencesNanocapsulesNanoscience and technologyPolysaccharidesCell Line TumormedicineHumansRaïmsWaste ProductsPlant ExtractsPrebioticlcsh:RPomaceHealth carePolyphenolsGreen Chemistry TechnologyHydrogen PeroxideNanostructuresIntestinal Diseases030104 developmental biologyPrebioticschemistryBiofilmsLiposomeslcsh:Q030217 neurology & neurosurgery
researchProduct

GLP-1 Analog Liraglutide Improves Vascular Function in Polymicrobial Sepsis by Reduction of Oxidative Stress and Inflammation

2021

Sepsis causes high mortality in the setting of septic shock. LEADER and other trials revealed cardioprotective and anti-inflammatory properties of glucagon-like peptide-1 (GLP-1) analogs like liraglutide (Lira). We previously demonstrated improved survival in lipopolysaccharide (LPS)-induced endotoxemia by inhibition of GLP-1 degradation. Here we investigate the effects of Lira in the polymicrobial sepsis model of cecal ligation and puncture (CLP). C57BL/6J mice were intraperitoneally injected with Lira (200 µg/kg/d

0301 basic medicineLipopolysaccharidePhysiologyglucagon-like peptide-1 (GLP-1)Clinical Biochemistryperitoneal and polymicrobial sepsisInflammationRM1-950030204 cardiovascular system & hematologyPharmacologymedicine.disease_causeBiochemistryArticleendothelial dysfunctionSepsis03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineoxidative stressvascular inflammationEndothelial dysfunctionInterleukin 6Molecular Biologyliraglutidebiologybusiness.industrySeptic shockCell Biologybacterial infections and mycosesmedicine.diseasececal ligation and puncture (CLP)Nitric oxide synthase030104 developmental biologychemistrybiology.proteinTherapeutics. Pharmacologymedicine.symptombusinessOxidative stressincretinsAntioxidants
researchProduct

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

2018

The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of C-C chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. A randomized, double-blind, multinational phase 2b study enrolled subjects with NASH, a nonalcoholic fatty liver disease activity score [NAS] ≥4, and liver fibrosis (stages 1-3, NASH Clinical Research Network) at 81 clinical sites. Subjects (N = 289) were randomly assigned CVC 150 mg or placebo. Primary outcome was ≥2-point improvement in NAS and no worsening of fibrosis at year 1. Key secondary outcomes were: resolution of steatohepatitis and no worsening of fibrosis; improvement in fibrosis by ≥1 stag…

0301 basic medicineLiver CirrhosisMalePlacebo-controlled studyMedical Biochemistry and MetabolomicsGastroenterologyOral and gastrointestinallaw.inventionHepatitisNASH NAFLD CVC nonalcoholic fatty liver inflammationSteatohepatitis/Metabolic Liver Disease0302 clinical medicineRandomized controlled trialFibrosislawNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseaseeducation.field_of_studyCVCLiver DiseaseNASHImidazolesMiddle AgedTreatment OutcomeTolerabilityLiverSulfoxides6.1 PharmaceuticalsCCR5 Receptor Antagonists030211 gastroenterology & hepatologyOriginal ArticleFemalePatient SafetyAdultmedicine.medical_specialtyPopulationChronic Liver Disease and CirrhosisClinical Trials and Supportive ActivitiesClinical SciencesImmunologyPlacebo03 medical and health sciencesDouble-Blind MethodClinical ResearchInternal medicineNAFLDmedicinenonalcoholic fatty liverHumanseducationAgedHepatologyGastroenterology & Hepatologybusiness.industryEvaluation of treatments and therapeutic interventionsOriginal Articlesmedicine.diseaseequipment and suppliesSurgeryCVC; NAFLD; NASH; inflammation; nonalcoholic fatty liver030104 developmental biologyinflammationHuman medicineSteatohepatitisbusinessDigestive DiseasesBiomarkers
researchProduct